MECOM rearrangement (MECOM-R) is a biomarker for disease progression and inferior prognosis in AML patients [1,2,3,4,5] and is considered as a defining genetic abnormality for AML regardless of blasts count under the 5th World Health Organization Classification for hematologic malignancies [6]. Here, MECOM is linked to acute myeloid leukemia.